| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Biomarin Pharmaceutical Inc.'s insiders have reduced their positions by a net 17,557 shares worth roughly $1.2M.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 214.6K | $11.95M | - | |
| CFO | 123.3K | $6.86M | - | |
| VP | 84.1K | $4.68M | - | |
| VP | 61.0K | $3.40M | - | |
| Dir | 49.4K | $2.75M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 4, 2018 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 1,500 | $98.16 | $147,240.00 | -0.5% | |
| Aug 28, 2018 | Alan Lewis | Director | Sale+OE | 7,500 | $99.11 | $743,327.00 | -26.2% | |
| Aug 27, 2018 | Richard A Meier | Director | Sale+OE | 2,000 | $100.12 | $200,235.40 | -2.8% | |
| Aug 27, 2018 | Henry J Fuchs | President, Worldwide R& D | Sell | 25,000 | $99.50 | $2,487,500.00 | -16.1% | |
| Aug 21, 2018 | Alan Lewis | Director | Sell | 4,200 | $100.09 | $420,365.40 | -16.6% | |
| Aug 7, 2018 | Robert Baffi | EVP, Technical Operations | Sell | 5,173 | $105.00 | $543,165.00 | -6.7% | |
| Aug 7, 2018 | Brian Mueller64 | SVP, Corporate Controller | Sale+OE | 2,500 | $104.50 | $261,250.00 | -16.8% | |
| Jul 23, 2018 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 1,500 | $101.69 | $152,535.00 | -0.5% | |
| Jun 27, 2018 | V Bryan Lawlis53 | Director | Sale+OE | 2,150 | $93.52 | $201,068.00 | -10.1% | |
| Jun 22, 2018 | Brian Mueller64 | SVP, Corporate Controller | Sale+OE | 3,145 | $99.50 | $312,927.50 | -20.3% |